Mary Wilson
Well-known member
26 August 2020
Pre-clinical testing of The University of Queensland’s COVID-19 vaccine has produced positive indications about its potential effectiveness and manufacturability.
Project co-leader Associate Professor Keith Chappell has reported to the International Society for Vaccines on data from animal trials conducted by Viroclinics-DDL in the Netherlands.
“The neutralizing immune response created by our molecular clamp vaccine in animal models was better than the average level of antibodies found in patients who have recovered from COVID-19,” Dr Chappell said.
“In hamster models, the vaccine combined with the Seqirus MF59? adjuvant, provided protection against virus replication, and reduced lung inflammation following exposure to the virus...
... “The Phase 1 study being conducted in Queensland is progressing well and assuming the study demonstrates adequate safety and immune responses, data should be available in time for CSL to commence the required large-scale efficacy study before the end of the year.”
Queensland’s Innovation Minister Kate Jones said the results were a huge milestone in the development of a Queensland vaccine.
https://www.uq.edu.au/news/article/...-report-positive-results-pre-clinical-testing
Pre-clinical testing of The University of Queensland’s COVID-19 vaccine has produced positive indications about its potential effectiveness and manufacturability.
Project co-leader Associate Professor Keith Chappell has reported to the International Society for Vaccines on data from animal trials conducted by Viroclinics-DDL in the Netherlands.
“The neutralizing immune response created by our molecular clamp vaccine in animal models was better than the average level of antibodies found in patients who have recovered from COVID-19,” Dr Chappell said.
“In hamster models, the vaccine combined with the Seqirus MF59? adjuvant, provided protection against virus replication, and reduced lung inflammation following exposure to the virus...
... “The Phase 1 study being conducted in Queensland is progressing well and assuming the study demonstrates adequate safety and immune responses, data should be available in time for CSL to commence the required large-scale efficacy study before the end of the year.”
Queensland’s Innovation Minister Kate Jones said the results were a huge milestone in the development of a Queensland vaccine.
https://www.uq.edu.au/news/article/...-report-positive-results-pre-clinical-testing